Anavex Life Sciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Anavex Life Sciences Corp. (AVXL) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
Operating Activities
Net Income-46.38-43.00-47.51-47.98-37.91-26.28-26.29-17.25
Stock Based Compensation11.559.4416.3718.388.230.000.000.00
Change in Working Capital-4.222.832.035.36-1.150.121.30-0.85
Change in Accounts Receivable1.640.000.000.000.000.000.000.00
Change in Accounts Payable-5.385.310.50-0.910.750.000.000.00
Change in Other Working Capital-0.48-2.480.856.28-1.900.000.000.00
Other Operating Activities0.009.3616.8418.388.684.886.580.00
Net Cash from Operating Activities-39.04-30.81-27.79-24.24-30.38-21.29-18.53-12.58
Investing Activities
Net Cash from Investing Activities0.000.000.000.000.000.000.000.00
Financing Activities
Common Stock Issued12.1411.2827.8820.99153.2228.7517.838.17
Other Financing Activities-2.710.000.00-0.71-5.55-0.400.00-0.10
Net Cash from Financing Activities9.4311.9829.6521.29153.2428.3517.788.07
Summary
Net Change in Cash-29.61-18.841.87-2.95122.867.06-0.75-4.51
Cash at Beginning of Period132.19151.02149.16152.1129.2522.1922.9327.44
Cash at End of Period102.58-18.841.87149.1629.2529.2522.1922.93
Free Cash Flow-39.04-30.81-27.79-24.24-30.38-21.29-18.53-12.58
Supplemental Disclosures
Income Taxes Paid0.130.300.140.330.140.000.000.00